270 related articles for article (PubMed ID: 35785601)
1. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics.
Kaur A; Baldwin J; Brar D; Salunke DB; Petrovsky N
Curr Opin Chem Biol; 2022 Oct; 70():102172. PubMed ID: 35785601
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor agonists as cancer vaccine adjuvants.
Jeon D; Hill E; McNeel DG
Hum Vaccin Immunother; 2024 Dec; 20(1):2297453. PubMed ID: 38155525
[TBL] [Abstract][Full Text] [Related]
3. Study of Agonists of TLRs as Vaccine Adjuvants.
Mancini F; Micoli F; Rossi O
Methods Mol Biol; 2023; 2700():249-269. PubMed ID: 37603186
[TBL] [Abstract][Full Text] [Related]
4. An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.
Kayesh MEH; Kohara M; Tsukiyama-Kohara K
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835108
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.
Kaur A; Kannan D; Mehta SK; Singh S; Salunke DB
Expert Opin Ther Pat; 2018 Nov; 28(11):837-847. PubMed ID: 30280939
[TBL] [Abstract][Full Text] [Related]
6. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
Kumar S; Sunagar R; Gosselin E
Front Immunol; 2019; 10():1144. PubMed ID: 31191528
[TBL] [Abstract][Full Text] [Related]
7. Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants.
Ong GH; Lian BSX; Kawasaki T; Kawai T
Front Cell Infect Microbiol; 2021; 11():745016. PubMed ID: 34692565
[TBL] [Abstract][Full Text] [Related]
8. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.
Chakraborty S; Ye J; Wang H; Sun M; Zhang Y; Sang X; Zhuang Z
Front Immunol; 2023; 14():1227833. PubMed ID: 37936697
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases.
Yang JX; Tseng JC; Yu GY; Luo Y; Huang CF; Hong YR; Chuang TH
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214155
[TBL] [Abstract][Full Text] [Related]
10. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
11. Toll or toll-free adjuvant path toward the optimal vaccine development.
Ishii KJ; Akira S
J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
[TBL] [Abstract][Full Text] [Related]
12. TLR based therapeutics.
Dunne A; Marshall NA; Mills KH
Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
[TBL] [Abstract][Full Text] [Related]
13. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
Lahiri A; Das P; Chakravortty D
Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576
[TBL] [Abstract][Full Text] [Related]
14. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines.
Fujita Y; Taguchi H
Ther Deliv; 2012 Jun; 3(6):749-60. PubMed ID: 22838070
[TBL] [Abstract][Full Text] [Related]
15. Vaccine adjuvants: mechanisms and platforms.
Zhao T; Cai Y; Jiang Y; He X; Wei Y; Yu Y; Tian X
Signal Transduct Target Ther; 2023 Jul; 8(1):283. PubMed ID: 37468460
[TBL] [Abstract][Full Text] [Related]
16. Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands.
Toussi DN; Massari P
Vaccines (Basel); 2014 Apr; 2(2):323-53. PubMed ID: 26344622
[TBL] [Abstract][Full Text] [Related]
17. TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases.
Luchner M; Reinke S; Milicic A
Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33499143
[TBL] [Abstract][Full Text] [Related]
18. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
19. [Application of toll-like receptor agonists as an adjuvant component to malaria blood-stage vaccine].
Xie CB; Qian F; Xu HJ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2011 Oct; 29(5):389-93. PubMed ID: 24830205
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor agonists in cancer therapy.
Adams S
Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
